Expression Systems is a leading provider of innovative cell culture media, baculovirus molecular reagents and cell lines used in advanced biological therapies
BUFFALO GROVE, Ill. and DAVIS, Calif., Nov. 10, 2022 /PRNewswire/ — ANGUS Chemical Company (“ANGUS” or the “Company”), a leading global manufacturer and marketer of specialty ingredients for the life sciences and industrial markets, announced today that it has acquired Expression Systems, LLC (“Expression Systems”), a leading global manufacturer of cell culture media and related products and services. ANGUS is a portfolio company of Ardian and Golden Gate Capital.
Founded in 1997, Expression Systems is dedicated to supplying and servicing the baculovirus expression platform with innovative cell culture media formulations, as well as cell lines, molecular tools, reagents and contract services. Expression Systems operates from a headquarters in Davis, California and is cGMP compliant and ISO 13485 certified for its manufacturing and research activities.
“The acquisition of Expression Systems is an important step in expanding ANGUS’ leadership position in Life Sciences beyond biobuffers into specialty cell culture media, a strategic adjacency with high overlap in customer and product offerings. and ancillary services,” explained ANGUS President and CEO David Neuberger. “The combination of ANGUS and Expression Systems further strengthens our ability to deliver value through consistent, high-quality ingredients and services essential to all phases of bioprocessing, from early-stage biological development to large-scale commercial production.” .
Expression Systems is a well-recognized independent provider of specialty cell culture media and related products with a strong track record of quality and product innovation based on proprietary technology. The company specializes in the Baculovirus Expression Vector System (BEVS) and has extensive experience in the entire process, from gene optimization to protein purification. Expression Systems’ products are used primarily by structural biology researchers and biologics manufacturers to efficiently and cost-effectively produce certain drug candidates, protein-based therapies, vaccines and gene therapies.
“For more than 20 years, our family and dedicated employees have built a strong reputation with their customers by leveraging our world-renowned technical expertise in baculovirus expression platform and media manufacturing,” said Expression President and CEO. Systems, David Hedin. “As we look to the future of our business, it was clear that ANGUS was in the best position to provide new opportunities for our current and new customers, as well as our employees. ANGUS will enhance our position as a dedicated, service-focused, world leading vendor. to the segments of the biological industry that use the baculovirus expression platform”.
Achelous Partners, LLC acted as exclusive M&A advisor to Expression Systems, LLC in this transaction.
ABOUT ANGUS
ANGUS is a leading global manufacturer and marketer of specialty ingredients and consumables for biotech, pharmaceutical, consumer and industrial applications. The company innovates through its unique nitroalkane chemistries, including its flagship multifunctional additives AMP™ (aminomethyl propanol) and TRIS AMINO™ (tromethamine) buffers, which are produced in fully integrated ISO 9001-certified manufacturing facilities in the United States and Germany. . ANGUS serves its global clients through six regional Client Application Centers located in Chicago, Illinois; Paris France; Sao Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. The company is privately owned by Ardian and Golden Gate Capital, and is based in Buffalo Grove, Illinois. For more information, visit angus.com.
Follow ANGUS on Facebook, Twitter and LinkedIn.
FOR ADDITIONAL INFORMATIONANGUS Media RelationsScott C. Johnson 1 847-808-3769scjohnson@angus.com
Logo – https://mma.prnewswire.com/media/460234/ANGUS_Chemical_Company_Logo.jpg
View original content: enlace
